Pharma BD Deal Intelligence

Eli Lilly and Company / Loxo Oncology, Inc.

2019 · Acquisition/Merger · $8.0B · Complete

Eli Lilly acquired Loxo Oncology for approximately $8 billion ($235 per share) in an all-cash tender offer, gaining a precision oncology pipeline anchored by Vitrakvi (larotrectinib), the first tumor-agnostic TRK inhibitor approved by the FDA, and the RET inhibitor selpercatinib (LOXO-292).

Key facts

• Announced Jan 07, 2019
• Closed Feb 15, 2019
• Deal value $8.0B
• Deal type Acquisition/Merger
• Therapeutic area Oncology
• Indications NTRK fusion-positive solid tumors, RET-altered thyroid cancer, RET fusion-positive non-small cell lung cancer, B-cell malignancies
• Key assets Vitrakvi (larotrectinib) — FDA approved Nov 2018, selpercatinib (LOXO-292) — Phase I/II for RET-altered cancers, LOXO-305 (pirtobrutinib) — non-covalent BTK inhibitor, preclinical/Phase I, Precision oncology genomics-first drug development platform
• Mechanism TRK inhibitor (pan-TRKA/B/C), Selective RET kinase inhibitor, Non-covalent BTK inhibitor

← Browse all deals  ·  How we score deals